Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Vitiligo
Interventions: AMG 714, Placebo, nbUVB phototherapy; Biological · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 7
States / cities: Irvine, California • Sacramento, California • New Haven, Connecticut + 4 more

Conditions: Clostridium Difficile Associated Disease
Interventions: C. difficile vaccine, C. difficile vaccine +adjuvant; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Pembroke Pines, Florida • South Miami, Florida • Overland Park, Kansas + 1 more

Conditions: Sleep Disorders, Circadian Rhythm
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 42
States / cities: Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 39 more

Conditions: Exercise Program, Standard Care Control
Interventions: App-based exercise program, Standard of Care; Other
Lead sponsor: University of Florida; Other
Eligibility: 55 Years to 105 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Insomnia, Nicotine Dependence
Interventions: Eszopiclone, Bupropion; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Prader-Willi Syndrome
Interventions: Pitolisant tablet, Placebo tablet; Drug · Other
Lead sponsor: Harmony Biosciences Management, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 23
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 16 more

Conditions: Fracture
Interventions: Vitamin D3, Placebo; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis
Interventions: Placebo, PF-06865571, PF-05221304; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 184
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 101 more

Conditions: Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)
Interventions: MET097 Injection, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 29
States / cities: Bessemer, Alabama • Chula Vista, California • Glendale, California + 23 more

Conditions: Chronic Low-back Pain, Anxiety, Depression
Interventions: EaseVRx, Sham VR; Device
Lead sponsor: AppliedVR Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,093 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Van Nuys, California

Conditions: Diverticulitis
Interventions: Mesalazine, Placebo; Drug
Lead sponsor: Dr. Falk Pharma GmbH; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New Smyrna Beach, Florida

Conditions: Stomatitis
Interventions: CG53135-05, velafermin; Drug
Lead sponsor: CuraGen Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 9
States / cities: La Jolla, California • Denver, Colorado • Miami, Florida + 6 more

Conditions: Acute Coronary Syndromes
Interventions: Apixaban, vitamin K antagonist, Acetylsalicylic acid, Acetylsalicylic acid placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 4,614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 143
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 125 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 30
States / cities: Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 27 more

Conditions: Alzheimer Disease
Interventions: ONO-2020, Placebo; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 60
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 53 more

Conditions: Hypertension, Vascular Stiffness
Interventions: Extra Virgin Olive Oil, Control Oil; Dietary Supplement
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Chronic Kidney Injury
Interventions: CXA-10, CXA-10 placebo; Drug
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Orthodontic Discomfort, Pain, Orofacial
Interventions: 3M Unitek 0.016 orthodontic archwire, Device: 0.016" Ormco 27oC NiTi orthodontic archwire, Device: 0.016" Ormco 35oC NiTi orthodontic archwire; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years and older
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: Setanaxib, Pembrolizumab, Placebo; Drug · Biological
Lead sponsor: Calliditas Therapeutics Suisse SA; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 5
States / cities: Miami Beach, Florida • City of Saint Peters, Missouri • Creve Coeur, Missouri + 2 more

Conditions: Treatment Resistant Depression
Interventions: PCN-101, Placebo; Drug
Lead sponsor: Perception Neuroscience; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 13
States / cities: Little Rock, Arkansas • Garden Grove, California • La Jolla, California + 10 more

Conditions: Parkinson's Disease
Interventions: FB-101, Placebo; Drug
Lead sponsor: 1ST Biotherapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chickenpox
Interventions: Investigational varicella vaccine, Marketed varicella vaccine, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 22
States / cities: Phoenix, Arizona • Tucson, Arizona • Huntington Park, California + 18 more

Conditions: Healthy
Interventions: CS-8080, placebo tablets; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Hormone Refractory Prostate Cancer
Interventions: AT-101, prednisone and docetaxel, placebo, prednisone and docetaxel; Drug
Lead sponsor: Ascenta Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 24
States / cities: Colorado Springs, Colorado • New Port Richey, Florida • Ocoee, Florida + 21 more

Search by objective public record fields.

Evaluation of AMG 714 for Vitiligo

Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years

Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase Syndrome

Home-based Digital Exercise Training Program to Improve Physical Function of Older Sepsis Survivors - HEAL Sepsis Trial

Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban

A Study of Pitolisant in Patients With Prader-Willi Syndrome

Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

EaseVRx-8w+ for the Treatment of Chronic Lower Back Pain

Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis

Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

Cardiovascular Effects of EVOO in Healthy Reproductive-aged Women

Oral CXA-10 Study in Healthy Volunteers

Comparison of Patient-reported Pain After Initial Archwire Placement

A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD

Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

Effects of Multiple Doses of CS-8080 in Healthy Volunteers

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)